Free tool
FAERS Monitor: Rybrevant
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761210 or its brand name (Rybrevant, Amivantamab-Vmjw). Reports on generic versions are filed under their own applications.
Reports
3,576
Serious
2,464
69% of reports
Hospitalization
748
Death reported
273
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- infusion related reaction756
- rash507
- off label use267
- paronychia178
- dyspnoea128
- non-small cell lung cancer118
- nausea117
- skin toxicity89
- oxygen saturation decreased88
- stomatitis87
- fatigue84
- hypotension84
- death80
- diarrhoea80
- flushing80
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 66 |
| 2022 | 154 |
| 2023 | 203 |
| 2024 | 592 |
| 2025 | 1,482 |
| 2026 | 1,079 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,583 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| paronychiaSignal | 178 | 248.2 | 214.4 | 41,830 |
| non-small cell lung cancerSignal | 118 | 148.5 | 124.1 | 16,725 |
| skin toxicitySignal | 89 | 94.1 | 76.5 | 7,979 |
| infusion related reactionSignal | 756 | 67.8 | 63.7 | 49,310 |
| oxygen saturation decreasedSignal | 88 | 9.2 | 7.5 | 638 |
| stomatitisSignal | 87 | 8.4 | 6.9 | 565 |
| rashSignal | 507 | 6.8 | 6.3 | 2,577 |
| flushingSignal | 80 | 4.6 | 3.7 | 225 |
| hypotensionSignal | 84 | 2.5 | 2.0 | 72 |
| off label use | 267 | 1.8 | 1.6 | 97 |
| dyspnoea | 128 | 1.3 | 1.1 | 10 |
| nausea | 117 | 0.9 | 0.7 | 2 |
| diarrhoea | 80 | 0.7 | 0.6 | 8 |
| fatigue | 84 | 0.6 | 0.5 | 18 |
| death | 80 | 0.5 | 0.4 | 31 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.